JP2023515687A - 大環状化合物の治療使用 - Google Patents

大環状化合物の治療使用 Download PDF

Info

Publication number
JP2023515687A
JP2023515687A JP2022552626A JP2022552626A JP2023515687A JP 2023515687 A JP2023515687 A JP 2023515687A JP 2022552626 A JP2022552626 A JP 2022552626A JP 2022552626 A JP2022552626 A JP 2022552626A JP 2023515687 A JP2023515687 A JP 2023515687A
Authority
JP
Japan
Prior art keywords
cancer
met
alkyl
compound
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515687A5 (https=
Inventor
ウィリアム マリー，ブライオン
ジャイ，ダヨン
ジェイ ツイ，ジンロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Turning Point Therapeutics Inc
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of JP2023515687A publication Critical patent/JP2023515687A/ja
Publication of JP2023515687A5 publication Critical patent/JP2023515687A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2022552626A 2020-03-02 2021-03-01 大環状化合物の治療使用 Pending JP2023515687A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984159P 2020-03-02 2020-03-02
US62/984,159 2020-03-02
PCT/US2021/020255 WO2021178296A1 (en) 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds

Publications (2)

Publication Number Publication Date
JP2023515687A true JP2023515687A (ja) 2023-04-13
JP2023515687A5 JP2023515687A5 (https=) 2024-03-07

Family

ID=77613771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552626A Pending JP2023515687A (ja) 2020-03-02 2021-03-01 大環状化合物の治療使用

Country Status (11)

Country Link
US (1) US20250262216A1 (https=)
EP (1) EP4114530A4 (https=)
JP (1) JP2023515687A (https=)
KR (1) KR20230022151A (https=)
CN (1) CN115397514A (https=)
AU (1) AU2021229457A1 (https=)
BR (1) BR112022017425A2 (https=)
CA (1) CA3174455A1 (https=)
IL (1) IL295938A (https=)
MX (1) MX2022010945A (https=)
WO (1) WO2021178296A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111902417B (zh) 2018-04-25 2023-07-28 北京普祺医药科技股份有限公司 一种二芳基巨环化合物、药物组合物以及其用途
US20240132517A1 (en) * 2021-02-10 2024-04-25 Goharmony Therapeutics (Shenzhen) Co., Ltd. Macrocyclic compound, pharmaceutical composition, and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023417A1 (en) * 2017-07-28 2019-01-31 Tp Therapeutics, Inc. MACROCYCLIC COMPOUNDS AND USES THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
RU2765181C2 (ru) * 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
US10689400B2 (en) * 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
CN114423762B (zh) * 2019-09-30 2024-03-29 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023417A1 (en) * 2017-07-28 2019-01-31 Tp Therapeutics, Inc. MACROCYCLIC COMPOUNDS AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. Vol. 79, No. 13, Suppl., JPN6025002594, July 2019 (2019-07-01), pages 1321, ISSN: 0005651313 *

Also Published As

Publication number Publication date
US20250262216A1 (en) 2025-08-21
AU2021229457A1 (en) 2022-10-20
IL295938A (en) 2022-10-01
CN115397514A (zh) 2022-11-25
BR112022017425A2 (pt) 2022-11-29
EP4114530A4 (en) 2024-04-17
MX2022010945A (es) 2022-10-07
CA3174455A1 (en) 2021-09-10
WO2021178296A1 (en) 2021-09-10
KR20230022151A (ko) 2023-02-14
EP4114530A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
US12310968B2 (en) Chiral diaryl macrocycles and uses thereof
US9657008B2 (en) Chemical compounds
CN112375078B (zh) 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
JP2020514409A (ja) ジアリール大環状化合物を含む併用療法
JP2023515687A (ja) 大環状化合物の治療使用
Levine Janus kinase mutations
Hernandez 3H-PYRAZOLO [4, 3-F] QUINOLINE MOIETY AS A NOVEL PRIVILEGED KINASE INHIBITOR
Hou et al. STX-478, RLY-2608, and LOXO-783: third-generation PIK3CA mutant-selective allosteric inhibitors
HK1214592B (en) Chemical compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250729